MAP2K7 and cholangiocarcinoma: Indeed, Bendell and colleagues also demonstrated a PR in cholangiocarcinoma treated with a MEK 1/2 inhibitor.[17] Although KRAS mutations may sensitize a tumor to MEK inhibitors,[18] the KRAS status of our patient with prolonged stable disease on a novel MEK inhibitor was unknown due to lack of tissue available for molecular analysis.